RESTON, Va. & SAN DIEGO--(BUSINESS WIRE)--The Epilepsy Research Foundation, a collaboration of several non-profit organizations, including the Epilepsy Foundation, the Epilepsy Therapy Development Project and Finding a Cure for Epilepsy and Seizures (FACES), together with the Milken Family Foundation, a private philanthropic foundation, today announced recipients of translational research funds totaling over $400,000 to advance three promising new epilepsy therapies. These awards, which support the advancement of new therapies through translational research and potentially early clinical development, are being presented to physicians and scientists developing promising treatments with high-impact, near-term patient benefits. The funded projects include a Phase IIa clinical trial of a compound derived from a Chinese herb - the first modern era clinical study of an herbal-derived compound for epilepsy, research of a galanin-based therapy for a much-needed new treatment of refractory epilepsy, and the development of biodegradable adenosine-releasing brain implants for the treatment of temporal lobe epilepsy. The announcements were made during the annual meeting of the American Epilepsy Society, the professional organization of epilepsy care providers and scientists convened in San Diego, CA.
